reports
Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYP...
Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29th at 2:00pm ET LAGUNA HILLS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it has acquired an additional 108,594 HYPE tokens, expanding its total holdings to 1,535,772 HYPE purchased at an average price of $36.14 per token. This latest purchase is in preparation of deploying HYPE into Kinetiq’s iHYPE (“Institutional HYPE”) po...
Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evol...
Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025 LAGUNA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it will host a special corporate update event on Tuesday, July 29, 2025 at 2:00 PM ET with CIO Hyunsu Jung and CEO Michael Rowe, to discuss the Company's bold transformation from a digital ophthalmic tech company into the first publicly-listed U.S. firm focused on building a strategic treasury around HYP...
Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings
Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings Increases total holdings to 1,427,178 HYPE LAGUNA HILLS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 120,726 HYPE tokens, expanding its total holdings to 1,427,178 HYPE purchased at an average price of $35.38 per token. “This latest acquisition...
Eyenovia Announces Rebranding and Corporate Name Change to Hyperion De...
Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, th...
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparat...
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement Increases total holdings to 1,306,452 HYPE LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 pe...
Eyenovia Announces Co-Branded Validator with Kinetiq
Eyenovia Announces Co-Branded Validator with Kinetiq Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holders LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem. The validator mar...
Eyenovia Announces Closing of $50 Million Private Placement, Successfu...
Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for September 2025; meaningful partnering discussions ongoing LAGUNA HILLS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Com...
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asse...
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capita...
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYP...
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”) today announced that it has entered into a securities purchase agreement (the “SPA”) for a $50 million private placement in public equity (the “PIPE Financing”) with institutional...
Eyenovia Provides Updates on Potential Merger with Betaliq and Develop...
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif....
Eyenovia Provides Development Update on Optejet User Filled Device (UF...
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company’s novel Optejet UFD. The user-filled Optejet is designed to work with a...
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Me...
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing an...
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirem...
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low...
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Sen...
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has entered in...
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dis...
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including difficul...
Eyenovia Announces 1-for-80 Reverse Stock Split
Eyenovia Announces 1-for-80 Reverse Stock Split Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that its Board of Directors approved a 1-for-80 reverse stock split (the “Reverse Sto...
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, ...
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company, today announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“...
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternativ...
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. ...
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Off...
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warran...
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Off...
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu thereof) and warrant...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.